trending Market Intelligence /marketintelligence/en/news-insights/trending/VX3CUUiCf9YeW_hcW9mzzA2 content esgSubNav
In This List

Paratek's acne treatment clears phase 3 trial, Allergan to seek approval

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Paratek's acne treatment clears phase 3 trial, Allergan to seek approval

Paratek Pharmaceuticals Inc.'s sarecycline met its primary endpoints in two phase 3 trials for the treatment of moderate to severe acne.

Allergan PLC owns the U.S. rights to the treatment and plans to file a new drug application with the U.S. FDA during the second half of 2017 based on the results.

"The positive efficacy results observed in the pivotal phase 3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne," Allergan Chief Global Research & Development Officer David Nicholson said in a statement.